16,400 resources
Start Prev Rows 7000 - 7200 Next
| Package | Version | Identity | Name/Title | Status | FMM | WG | Date |
|---|---|---|---|---|---|---|---|
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.439 | T Category | active | 2018-05 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.440 | N Category | active | 2018-05 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.441 | M Category | active | 2018-05 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.442 | TNM Stage Group | active | 2018-05 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.449 | Opioids | active | 2024-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.492 | Pharmacological interventions for depression | active | 2024-05 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.535 | Ovarian Cancer | active | 2023-05 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.536 | Ovarian Cancer | active | 2023-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.537 | Fallopian Tube Cancer | active | 2022-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.539 | Fallopian Tube Cancer | active | 2022-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.541 | Peritoneal Cancer | active | 2022-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.542 | Peritoneal Cancer | active | 2023-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.547 | Cancer Stage 1C | active | 2024-12 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.555 | Gender Female | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.556 | Gender Male | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.557 | Pathological N Stage N3a | active | 2024-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.558 | Pathological N Stage N3b | active | 2024-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.560 | Rolapitant Oral | active | 2024-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.599 | Obinutuzumab Injectable | active | 2024-12 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.600 | Ofatumumab Injectable | active | 2024-12 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.602 | Neurokinin 1 Receptor Antagonist | active | 2024-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.604 | Serotonin Receptor Antagonist | active | 2025-04 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.61 | Cetuximab Injectable | active | 2024-12 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.63 | Panitumumab Injectable | active | 2024-12 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.81 | Palonosetron Oral | active | 2024-12 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.88 | Lung Cancer | active | 2015-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.89 | Lung Cancer | active | 2023-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.95 | M Stage M0 | active | 2024-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.97 | Pathological M Stage M1 | active | 2024-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.98 | Pathological M Stage M1a | active | 2024-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1116.99 | Pathological M Stage M1b | active | 2024-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1125.7 | PROMIS Depression Assessment | active | 2023-05 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1130.11 | Sleep Apnea | active | 2018-05 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1130.13 | Septic Shock due to C. Diff | active | 2019-04 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1130.15 | Body Temperature | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1130.16 | Diarrhea Potentially due to CDI | active | 2019-04 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1130.17 | Abdominal Distension | active | 2019-04 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1130.18 | Vomiting potentially due to CDI | active | 2019-04 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1130.19 | Ileus due to infection | active | 2019-04 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1130.20 | Clostridium difficile infection | active | 2019-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1130.3 | Radiation Therapy Indicators from CPT | active | 2017-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1130.4 | Diagnostic Radiology Surrounding Face and Sinus | active | 2017-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1130.5 | Ear Surgery Affecting the Tympanic Membrane | active | 2017-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1130.6 | Allergic Rhinitis Immunotherapy | active | 2017-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1130.8 | Radiology to Head and Sinus | active | 2017-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1130.9 | Immunotherapy For Allergic Rhinitis | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1136.63 | Aortic Dissection or Ruptured Aortic Aneurysm | active | 2024-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.1 | C2S Alcohol Use Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.11 | C2S Amphetamine Use Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.12 | C2S Cannabis Use Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.13 | C2S Cannabis Use Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.14 | C2S Cannabis Use Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.15 | C2S Cannabis Use DIsorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.16 | C2S Cocaine Use Disorder | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.17 | C2S Cocaine Use Disorder | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.18 | C2S Cocaine Use Disorder | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.19 | C2S Hallucinogens | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.2 | C2S Alcohol Use Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.20 | C2S Hallucinogens | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.21 | C2S Hallucinogens | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.22 | C2S Hallucinogens | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.23 | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.24 | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.25 | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.26 | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.27 | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.28 | C2S Inhalants | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.29 | C2S Inhalants | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.3 | C2S Alcohol Use Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.30 | C2S Inhalants | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.32 | C2S Mental Health Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.33 | C2S Mental Health Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.34 | C2S Mental Health Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.35 | C2S Mental Health Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.36 | C2S Mental Health Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.38 | C2S Opioids | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.39 | C2S Opioids | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.4 | C2S Alcohol Use Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.40 | C2S Opioids | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.42 | C2S Opioids | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.43 | C2S Other Psychoactive Substance Use Disorder | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.44 | C2S Other Psychoactive Substance Use Disorder | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.45 | C2S Other Psychoactive Substance Use Disorder | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.46 | C2S Sedative Hypnotic, or anxiolytic related disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.47 | C2S Sedative Hypnotic, or anxiolytic related disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.48 | C2S Sedative Hypnotic, or anxiolytic related disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.49 | C2S Sexuality and reproductive health information sensitivity | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.5 | C2S Alcohol Use Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.51 | C2S Tobacco Use Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.52 | C2S Tobacco Use Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.53 | C2S Tobacco Use Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.54 | C2S Tobacco Use Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.55 | C2S Substance Use Information Sensitivity | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.56 | C2S Substance Use Information Sensitivity | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.58 | C2S Sensitive Categories | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.59 | C2S Opioids | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.6 | C2S Amphetamine Use Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.60 | C2S HIV/AIDS information Sensitivity | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.65 | Test C2S Alcohol Use Disorders | active | 2019-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.67 | Test C2S HIV/AIDS Information Sensitivity | active | 2019-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.7 | C2S Amphetamine Use Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.8 | C2S Amphetamine Use Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1142.9 | C2S Amphetamine Use Disorders | active | 2016-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.10 | Diphtheria (Tests for Corynebacterium diphtheriae by Culture and Identification Method) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1002 | Tuberculosis (Tests for Mycobacterium species by Culture and Identification Method) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1012 | S. Typhi Infection (Disorders) (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1016 | S. Paratyphi Infection (Disorders) (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1017 | S. Typhi Infection (Tests for S. Typhi by Culture and Identification Method) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1021 | Dark Urine (SNOMED) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1022 | Acute Onset [Qualifier Value] (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1024 | Acute Viral Hepatitis (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1027 | Sepsis [Septicemia] [Bacterial] [Unspecified Organism] (ICD10CM) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1029 | Listeriosis [Listeria species] (Organism or Substance in Lab Results) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1030 | Meningitis [Unspecified Cause] (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1032 | Encephalitis [Unspecified Cause] (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1033 | Encephalitis [Unspecified Cause] (SNOMED) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1035 | Indeterminate or Equivocal Lab Result Value | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1037 | Smoking Status [Current Nonsmoker] (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1040 | Organisms (Tests by Unspecified Method) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1041 | Organisms (Tests by Culture and Identification) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1044 | Candida auris Infection (Tests for Candida auris by Culture and Identification Method) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1045 | Candida auris Infection (Tests for Candida auris Nucleic Acid) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1047 | Parkinson’s disease (Disorders) (ICD10CM) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1048 | Parkinson’s disease (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1049 | Parkinsonism [Secondary] (ICD10CM) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1050 | Parkinsonism [Secondary] (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1065 | Consciousness [Decreased Level] (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1071 | Drug Use [IV Evidence] (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1072 | Miosis (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1076 | Opioid Overdose and Poisoning (Tests for Opioids [Quantitative]) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1083 | Rash [Pustular Vesicular] (SNOMED) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1084 | Salivary Gland Swelling [Unspecified Cause] (Disorders) (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1090 | Syphilis [Congenital] (Disorders) (SNOMED) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1091 | Cataracts [Nonspecific]/Congenital glaucoma [Unspecified Cause] (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1092 | Congenital heart disease (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1093 | Hearing impairment (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1095 | Microcephaly (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1096 | Developmental delay (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1099 | Congenital heart disease (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1100 | Hearing impairment (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1104 | Developmental delay (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1106 | Listeriosis (Tests for Listeria monocytogenes Nucleic Acid in Specimen from Normally Sterile Site) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.112 | Tetanus (Disorders) (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1130 | Tickborne Relapsing Fever (Tests for Borrelia hermsii/miyamotoi/parkerii/turicatae Nucleic Acid) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1131 | Lyme Disease (Tests for Borrelia afzelii/garinii IgG Antibody by Immunoassay | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1138 | Staphylococcus Aureus (Tests by Culture and Identification Method) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1139 | VISA/VRSA (Tests for Vancomycin Resistance Gene) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1145 | Resistant Lab Result Value | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1148 | Tests for Vancomycin Susceptibility [Ord] | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1149 | Proteinuria (Tests for Total Protein in 24H Urine) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.115 | Mumps (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1150 | Thrombocytopenia (Tests for Platelets [#/volume] in Blood) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1156 | Staphylococcus aureus (Organism or Substance in Lab Results) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1169 | Chikungunya Virus Disease (Tests for Chikungunya virus Nucleic Acid) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.117 | Mumps (Disorders) (ICD10CM) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1180 | Chikungunya Virus Disease (Tests for Chikungunya Virus Antibody [Quantitative]) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1186 | Eastern Equine Encephalitis Virus Disease (Tests for Eastern Equine Encephalitis Virus Antibody [Qualitative]) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1188 | Western Equine Encephalitis Virus Disease (Tests for Western Equine Encephalitis Virus Antibody [Qualitative]) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1196 | Anthrax (Tests for Bacillus cereus by Culture and Identification Method) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1197 | Cervical Lymphadenitis (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1207 | CRE (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1212 | Enterobacteriaceae species [Carbapenem Resistant] (Organism or Substance in Lab Results) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1213 | NU_Enterobacteriaceae [Carbapenemase Producing] (Organism or Substance in Lab Results) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1214 | Carbapenemase resistance mechanism (Organism or Substance in Lab Results) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1215 | Tests for carbapenemase production | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1216 | Tests for carbapenemase resistance mechanism | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1217 | Tests for carbapenem susceptibility [Meropenem, imipenem, and doripenem] | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1218 | Tests for carbapenem susceptibility [Ertapenem] | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1219 | Tests for Enterobacter spp., E. coli, or Klebsiella spp. by Culture and Identification Method | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1220 | NU_Tests for Enterobacteriaceae species by Culture and Identification Method | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1224 | Therapeutic Response to Medication [Improved] | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1225 | Altered Mental Status (SNOMED) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1230 | Eschar (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1231 | Hypotension (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1233 | Localized Edema (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1234 | Localized Edema (ICD10CM) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1237 | Tachycardia (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1238 | Tachycardia (ICD10CM) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1239 | RCKMS Conditions (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.124 | Poliomyelitis (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1240 | Maternal Condition Puerperium (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1242 | Non pestis Yersiniosis Infection (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1244 | Blastomycosis (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1246 | Blastomycosis (Organism or Substance in Lab Results) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1249 | Blastomycosis (Tests for Blastomyces species by Culture and Identification Method) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1250 | Non pestis Yersiniosis Infection (Tests for Yersinia non pestis species Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1251 | Blastomycosis (Tests for Blastomyces species Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1252 | Blastomycosis (Tests for Blastomyces species Antibody) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1253 | Blastomycosis (Tests for Blastomyces species Antigen) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1265 | Fatigue (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1269 | Tuberculosis [Latent Infection] (Disorders) (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1274 | Histoplasmosis (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1275 | Histoplasmosis (Disorders) (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1281 | Histoplasmosis (Tests for Histoplasma capsulatum H band or M band Antibody) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1294 | Abscess [Liver, Lung, Spleen, Prostate, or Brain] (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1295 | Seizure [Unspecified Cause] (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1298 | Abscess [Liver, Lung, Spleen, Prostate, or Brain] (ICD10CM) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1299 | Seizure [Unspecified Cause] (ICD10CM) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.130 | Influenza (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1304 | Mycobacteria_Infection_NonTB_ExPulm (Tests for Mycobacterium species in Extrapulmonary Specimen by Culture and Identification Method) | active | 2025-02 |
FHIR